Xining Bio Completes Nearly RMB 100 Million Series A Financing to Advance Clinical Testing Services for Biologics

VCBeat has learned that Xining Bio announced the completion of its nearly RMB 100 million Series A financing round. The round was led by Sherpa Healthcare Partners, with participation from GT Capital and other investors. The funds will be used to enhance technical service capabilities and production capacity in the field of cell and gene therapy.

Previously, Accurant BioTech had completed angel and Pre-A financing rounds totaling tens of millions of RMB.

Xining Biotech was founded in October 2017,It is one of the few contract research organizations (CROs) in the market that specializes in providing macromolecule bioanalysis services for pharmaceutical R&D.The company’s core management team has an average of nearly 20 years of industry experience and has participated in the drafting and review of multiple domestic and international regulations, such as the “Guidelines for Bioanalytical Method Validation” in the Chinese Pharmacopoeia 2015 Edition and several international industry white papers. With deep expertise in their specialized field, the team has supported over 200 global multi-center clinical trials and more than 100 types of large-molecule products, providing data support for regulatory approval submissions of multiple blockbuster drugs worldwide.

Xining Biotech has established laboratories compliant with GLP and GCP quality standards in three locations: Ningbo (Accurant BioTech), Shanghai (Shanghai Jinghan Biotechnology Co., Ltd.), and New Jersey, USA (Accurant Biotech Inc.), to meet the R&D and regulatory submission needs of clients both domestically and internationally.

Over the past three years, the Accurant BioTech team has grown to more than 100 members, with rapid expansion in business scale. The company has accumulated extensive practical experience in emerging fields such as bispecific/multispecific antibody drugs, cell therapy products (e.g., CAR-T), and gene therapy products, establishing strong competitive advantages in the industry.

Currently, Accurant BioTech has established partnerships with nearly 100 biopharmaceutical companies both domestically and internationally., including traditional first-tier pharmaceutical companies and innovative biotech firms. The collaborative projects cover multiple hot therapeutic areas such as tumor immunology, autoimmune diseases, and glucose-lowering therapies, encompassing various biological macromolecules including peptides, recombinant proteins, fusion proteins, monoclonal antibodies, bispecific antibodies, nanobodies, antibody-drug conjugates (ADCs), oncolytic viruses, and CAR-T cells.

Over the past two years, Accurant BioTech has gradually established its competitive advantages in bispecific antibodies and gene therapy products, particularly in technical services for cell therapy products. The company has supported clinical testing (including Phase I and II trials) for more than 10 cell therapy products and provided data support for the Biologics License Application (BLA) of JW Therapeutics’ CAR-T product.

Upon completion of this financing round, Accurant BioTech will further enhance its service capabilities and technical production capacity in the field of cell and gene therapy, rapidly expand into the companion diagnostics sector, and strengthen its technical support services for clinical research on oncology drugs.On its path forward, Accurant BioTech has chosen a broad and promising track: with the booming development of the biopharmaceutical industry and the increasing specialization and division of labor in R&D models, CRO companies serving various specialized niche sectors are poised for rapid growth.

Cai Daqing, Managing Partner at Sherpa, the lead investor in this round, stated:“As Chinese macromolecule and biotechnology companies progressively enter clinical trial phases, high-quality bioanalytical CRO services are in short supply. The team at Accurant BioTech possesses globally leading analytical testing capabilities and has accumulated extensive experience serving benchmark pharmaceutical companies both domestically and internationally, earning widespread acclaim. Sherpa will fully support Accurant BioTech in scaling up and strengthening its operations, thereby contributing to the development of China’s pharmaceutical industry.”

Sherpa is a specialized fund focused on early-stage healthcare investments. Adhering to an investment philosophy centered on building industry ecosystems, it constructs its portfolio around rigid, unmet medical needs based on in-depth expertise in the treatment of major diseases, while strategically deploying capital across the industry’s vertical depth and upstream-downstream value chain.

By actively sharing operational expertise and forward-looking, full-industry-chain insights with portfolio companies, the team proactively fosters internal and external synergy, helping enterprises achieve rapid growth in business performance and valuation while securing leading positions in their respective niche markets. The firm has invested in industry-leading companies across key sectors such as healthcare services, pharmaceuticals, gene technology, and medical devices, thereby cultivating comprehensive resource advantages spanning deal sourcing, post-investment value-added services, and exit strategies. From 2011 to 2020, through four fund vintages and the rigorous experience of managing over 100 healthcare projects, we have had the privilege of partnering with numerous outstanding entrepreneurs, growing together along the journey.

Junxin Capital is a fully market-oriented private equity investment platform under the Juneyao Group-Aijian Group. It actively lays out its investments in the two major sectors of information technology and healthcare, focusing on leading enterprises in various niche segments of these industries. The firm prioritizes investments in technology-driven growth companies characterized by “advanced technology + import substitution” and “advanced technology + enterprise services.”

Leveraging GT Capital’s robust shareholder resources, top-tier institutional investor network, and a strategically built cross-regional, cross-industry alliance, we provide exceptional services to portfolio companies in corporate governance, strategic planning and execution, business expansion, IPOs, and M&A. We have established a certain industrial footprint in the healthcare sector, with portfolio companies such as Akeso and Haoyuan Pharmatech successfully listed on the capital markets.